These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 22123826)
1. A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein. Baldo B; Weiss A; Parker CN; Bibel M; Paganetti P; Kaupmann K J Biol Chem; 2012 Jan; 287(2):1406-14. PubMed ID: 22123826 [TBL] [Abstract][Full Text] [Related]
2. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202 [TBL] [Abstract][Full Text] [Related]
3. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922. Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G Cells; 2019 Sep; 8(10):. PubMed ID: 31569342 [TBL] [Abstract][Full Text] [Related]
4. The interaction between RE1-silencing transcription factor (REST) and heat shock protein 90 as new therapeutic target against Huntington's disease. Orozco-Díaz R; Sánchez-Álvarez A; Hernández-Hernández JM; Tapia-Ramírez J PLoS One; 2019; 14(7):e0220393. PubMed ID: 31361762 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Lee KH; Lee JH; Han SW; Im SA; Kim TY; Oh DY; Bang YJ Cancer Sci; 2011 Jul; 102(7):1388-95. PubMed ID: 21453385 [TBL] [Abstract][Full Text] [Related]
6. Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition. Chen Y; Chen J; Yu J; Yang G; Temple E; Harbinski F; Gao H; Wilson C; Pagliarini R; Zhou W J Biol Chem; 2014 Jul; 289(27):18914-27. PubMed ID: 24831003 [TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405 [TBL] [Abstract][Full Text] [Related]
8. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition. Schilling D; Garrido C; Combs SE; Multhoff G Cancer Lett; 2017 Apr; 390():146-152. PubMed ID: 28108313 [TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597 [TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells. Chiang MC; Cheng YC; Nicol CJ; Lin KH; Yen CH; Chen SJ; Huang RN Exp Cell Res; 2015 Nov; 338(2):183-93. PubMed ID: 26362846 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279 [TBL] [Abstract][Full Text] [Related]
12. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α. Stingl L; Niewidok N; Müller N; Selle M; Djuzenova CS; Flentje M Strahlenther Onkol; 2012 Jun; 188(6):507-15. PubMed ID: 22441439 [TBL] [Abstract][Full Text] [Related]
13. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Walsby E; Pearce L; Burnett AK; Fegan C; Pepper C Oncotarget; 2012 May; 3(5):525-34. PubMed ID: 22619113 [TBL] [Abstract][Full Text] [Related]
14. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351 [TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells. Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314 [TBL] [Abstract][Full Text] [Related]
17. Sensitizing tumor cells to radiation by targeting the heat shock response. Schilling D; Kühnel A; Konrad S; Tetzlaff F; Bayer C; Yaglom J; Multhoff G Cancer Lett; 2015 May; 360(2):294-301. PubMed ID: 25721082 [TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253 [TBL] [Abstract][Full Text] [Related]
19. Heat shock promotes inclusion body formation of mutant huntingtin (mHtt) and alleviates mHtt-induced transcription factor dysfunction. Chen JY; Parekh M; Seliman H; Bakshinskaya D; Dai W; Kwan K; Chen KY; Liu AYC J Biol Chem; 2018 Oct; 293(40):15581-15593. PubMed ID: 30143534 [TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Canonici A; Qadir Z; Conlon NT; Collins DM; O'Brien NA; Walsh N; Eustace AJ; O'Donovan N; Crown J Invest New Drugs; 2018 Aug; 36(4):581-589. PubMed ID: 29396630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]